About
Protein-splicing platform (split-intein AAV) to deliver large genes. Lead program SB-007 for Stargardt (ABCA4) in Phase 1/2 (ASTRA study), backed by EQT Life Sciences and Sanofi Ventures.
HQ: Barcelona, Spain
Funding
$135M Series B (Jun 2025)
—